Ignacio García-Ribas

Ignacio Garcia-Ribas is a medical oncologist with 17 years of experience in early-stage oncology drug development. Most recently he was Chief Medical Officer of the Swedish company Cantargia where he created and implemented the initial development plan for Nadunolimab in both Europe and USA. He previously worked at Takeda as global clinical lead on several Phase 1/2 programmes with a specific focus on immuno-oncology, and before that he was Senior Medical Director and a member of the Early Development Group of Sanofi’s Oncology Division where he was involved in the clinical development of small molecules and ADCs. Prior to that, he was part of the Early Development Unit at Eli Lilly, where he contributed to the development of several small molecules and antisense oligonucleotides. Dr. Garcia Ribas received his PhD in Medicine from the Richard Dimbleby Cancer Research Department/ICRF Unit at St. Thomas’ Hospital in London, which focused on cancer gene therapy.